The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
Andrea Necchi
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Patrizia Giannatempo
No relevant relationships to disclose
Daniele Raggi
No relevant relationships to disclose
Elena Farè
No relevant relationships to disclose
Alfonso Marchianò
No relevant relationships to disclose
Flavio Crippa
No relevant relationships to disclose
Elena Togliardi
No relevant relationships to disclose
Maria Grazia Daidone
No relevant relationships to disclose
Alessandro M. Gianni
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose